1
|
Dos Santos G, Wang H, Jindal P, Rybo M, Roul H, Pallem S, Eckermann T, Godderis L, Martínez Gómez X, Godard E, Soler M, Yousefi M, Salamanca de la Cueva I, Nwoji U. Brand-Specific Enhanced Safety Surveillance Study of GSK's Quadrivalent Seasonal Influenza Vaccine, Conducted During the COVID-19 Pandemic, in Belgium, Germany and Spain, for the 2020/21 Season. Infect Dis Ther 2021; 11:463-483. [PMID: 34961900 PMCID: PMC8711683 DOI: 10.1007/s40121-021-00571-y] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/2021] [Accepted: 11/17/2021] [Indexed: 12/22/2022] Open
Abstract
INTRODUCTION Seasonal influenza poses a major public health burden worldwide. Influenza vaccines, updated yearly to match circulating strains based on World Health Organization (WHO) recommendations, are the cornerstone of prevention and require regular monitoring. The COVID-19 pandemic is expected to cause logistical, site access and medical staff constraints and could affect the safety profile of influenza vaccines. METHODS Following European Medicines Agency guidance, an enhanced safety surveillance (ESS) study assessed the frequency and severity of predefined and other adverse events (AEs) occurring within 7 days of receiving GSK's inactivated quadrivalent seasonal influenza vaccine (IIV4), in Belgium, Germany and Spain in 2020/21, using adverse drug reaction (ADR) cards. RESULTS During the 2020/21 influenza season, 1054 participants vaccinated with GSK's IIV4 were enrolled (all adults in Belgium and Germany, 30% adults/70% children in Spain); 96 eligible children received a second dose. Overall, 1042 participants completed the study. After doses 1 and 2, 98.9% and 100% of participants, respectively, returned their completed ADR card. After doses 1 and 2, 37.8% (398/1054) and 13.5% (13/96) of participants, respectively, reported at least one AE. The most frequently reported categories of AEs were "general disorders and administration site conditions" (e.g. injection site pain) and "nervous system disorders" (e.g. headache). There were no deaths or serious AEs deemed related to GSK's IIV4. CONCLUSION This ESS study assessed AEs in near real time. The COVID-19 pandemic did not alter the safety profile of GSK's IIV4. No safety signals were detected during the study, which confirms the excellent safety profile of GSK's IIV4.
Collapse
Affiliation(s)
| | | | - Pooja Jindal
- Parexel International, Chandigarh, India, C/O GSK, Rockville, MD, USA
| | | | - Hélène Roul
- Keyrus Life Science, Levallois-Perret, France, C/O GSK, Wavre, Belgium
| | - Sridevi Pallem
- Keyrus Life Science, New York, NY, USA, C/O GSK, New York, NY, USA
| | | | - Lode Godderis
- Environment and Health, Department of Public Health and Primary Care, KU Leuven, Leuven, Belgium.,External Service for Prevention and Protection at Work, IDEWE, Heverlee, Belgium
| | | | | | - Muriel Soler
- 4Clinics, Waterloo, Belgium, C/O GSK, Wavre, Belgium
| | | | | | | |
Collapse
|
2
|
Montesinos-Sanchis E, Moraga-Llop FA, Soler-Palacín P, Oliveras-Arenas M, Larrosa Escartín MN, Martínez Gómez X, Figueras-Nadal C. [Carbapenem antibiotics in hospitalised paediatric patients. Adherence to a therapeutic protocol]. Enferm Infecc Microbiol Clin 2013; 32:647-53. [PMID: 24355607 DOI: 10.1016/j.eimc.2013.10.013] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/26/2012] [Revised: 10/06/2013] [Accepted: 10/16/2013] [Indexed: 10/25/2022]
Abstract
OBJECTIVE To describe the use of carbapenems in children hospitalised outside intensive care and onco-haematology units, and assess adherence to a therapeutic protocol. PATIENTS AND METHODS A retrospective observational study was conducted on the use of carbapenems between January 2009 and December 2010. The study included children with a community-acquired infectious disease or a health care-associated infectious disease, and who were admitted to paediatric areas of the Vall d'Hebron University Hospital (Barcelona, Spain), other than intensive care, neonatology and onco-haematology units. Clinical data were collected and antibiotic consumption data were provided by the Pharmacy Department. RESULTS A total of 51 episodes fulfilled the inclusion criteria. Carbapenem as initial empirical treatment was indicated in 31.4%, and applied as rescue therapy in the remainder. The instructions of the protocol were adhered to in 70.6% of the empirical and 87.5% of the targeted prescriptions (77.6% overall). A better match was found for empirical carbapenem in patients with a previous admission or underlying condition. Factors such as diagnosis, age or antibiotic use prior to admission did not affect the empirical indication of carbapenem. CONCLUSIONS The establishment of a treatment protocol with carbapenem indications in our centre since 2007 has yielded significantly better results on the appropriateness of the prescription than those obtained in other studies.
Collapse
Affiliation(s)
- Elena Montesinos-Sanchis
- Unidad de Patología Infecciosa e Inmunodeficiencias de Pediatría, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, España
| | - Fernando A Moraga-Llop
- Unidad de Patología Infecciosa e Inmunodeficiencias de Pediatría, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, España.
| | - Pere Soler-Palacín
- Unidad de Patología Infecciosa e Inmunodeficiencias de Pediatría, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, España
| | - María Oliveras-Arenas
- Servicio de Farmacia, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, España
| | - M Nieves Larrosa Escartín
- Servicio de Microbiología, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, España
| | - Xavier Martínez Gómez
- Servicio de Medicina Preventiva y Epidemiología, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, España
| | - Concepción Figueras-Nadal
- Unidad de Patología Infecciosa e Inmunodeficiencias de Pediatría, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, España
| |
Collapse
|
3
|
Uriona Tuma SM, Martínez Gómez X, Campins Martí M, Codina Grau G, Ferrer Marcelles A, Rodrigo Pendás JÁ, Pinós Tella L, Cebrian R, Moraga Llop FA. Estudio de contactos de casos pediátricos de tos ferina en un hospital de tercer nivel de Barcelona. Med Clin (Barc) 2013. [DOI: 10.1016/j.medcli.2012.09.017] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
4
|
Vilca Yengle LM, Campins Martí M, Cabero Roura L, Rodrigo Pendás JA, Martínez Gómez X, Hermosilla Pérez E, Vaqué Rafart J. [Influenza vaccination in pregnant women. Coverage, practices and knowledge among obstetricians]. Med Clin (Barc) 2009; 134:146-51. [PMID: 19942237 DOI: 10.1016/j.medcli.2009.10.004] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2009] [Accepted: 10/02/2009] [Indexed: 12/01/2022]
Abstract
BACKGROUND AND OBJECTIVES Women who are pregnant during influenza season have an increased risk of infection and severe clinical disease. Several national and international organizations currently recommend vaccination for pregnant women. We intended to estimate the influenza vaccination rate in a population of postpartum women attended in a tertiary hospital in Barcelona. Moreover, we assessed the knowledge and practice of obstetricians about influenza vaccination during pregnancy. METHODS Two cross-sectional surveys were performed. Postpartum women who delivered from December 2007 to February 2008 were included. The sample of obstetricians was constituted by those who were working in hospital or primary care reference areas. RESULTS Influenza vaccination rate was 4.1%. Healthy women represented 80.5% of our population. The vaccination rate in the group with comorbidities was 3.3%. The providers who recommended the vaccine more frequently were the midwife in 28.9% and the nurse in 18.4%. Among the obstetricians, 20.9% responded that the influenza vaccine was recommended in the first trimester of pregnancy and 65.1% said that it was recommended in the second or third trimester. In relation to practice, only 7% offered the vaccine in the first trimester and 20,9% in the second or third trimester. CONCLUSIONS The influenza vaccination rate in pregnant women in our study is very low. Obstetricians showed a low level of knowledge about the current influenza vaccination recommendations, mainly in the case of first trimester of pregnancy and only few offered the vaccine in their practice.
Collapse
Affiliation(s)
- Luz María Vilca Yengle
- Servei de Medicina Preventiva i Epidemiologia, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, España.
| | | | | | | | | | | | | |
Collapse
|
5
|
Vargas-Leguás H, Selva-O’Callaghan A, Campins-Martí M, Hermosilla Pérez E, Grau-Junyent JM, Martínez Gómez X, Vaqué Rafart J. Polimiositis y dermatomiositis: incidencia en España (1997-2004). Med Clin (Barc) 2007; 129:721-4. [DOI: 10.1157/13113285] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
6
|
Rodríguez-Martos Dauer A, Santamariña Rubio E, Martínez Gómez X, Torralba Novella L, Escayola Coris M, Martí Valls J, Plasència Taradach A. Identificación precoz e intervención breve en lesionados de tráfico con presencia de alcohol: primeros resultados. Adicciones 2003. [DOI: 10.20882/adicciones.427] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
7
|
Elorza Ricart JM, Campins Martí M, Martínez Gómez X, Allepuz Palau A, Ferrer Gramunt E, Méndez-Aguirre Guitián M. [Influenza vaccine and health-care workers: strategies to achieve compliance in a tertiary hospital]. Med Clin (Barc) 2002; 119:451-2. [PMID: 12385652 DOI: 10.1016/s0025-7753(02)73452-0] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
BACKGROUND The effectiveness of immunization of health-care workers (HCWs) to reduce nosocomial transmission of influenza is well established. The objective of this study is to evaluate HCWs vaccination rates in a tertiary hospital. PATIENTS AND METHOD Data of influenza immunization rates among HCWs during two consecutive campaigns have been examined. A descriptive analysis of coverage by age, sex, occupation and job areas is performed. RESULTS Vaccination rates ranged from 12.7 to 14.7%. Vaccine acceptance among medical residents was significantly higher than in other occupation categories (31.5 and 25.5%, respectively). HCWs at maternal and pediatric areas showed higher immunization rates. CONCLUSIONS Despite active immunization campaigns, influenza vaccination rates among HCWs are quite low.
Collapse
Affiliation(s)
- José María Elorza Ricart
- Servicio de Medicina Preventiva y Epidemiología. Hospital Vall d'Hebron. Universitat Autònoma de Barcelona. Barcelona. España
| | | | | | | | | | | |
Collapse
|